Edison Investment Research - Blue Cap (B7E) Blue Cap - Business as usual

Report

Edison Investment Research

Richard Finch

Blue Cap - Business as usual

Blue Cap's solid 2018 results were epitomised by a 15% rise in NAV and a positive trading statement. Management confidence in continued operational gains across the board and long-term turnaround potential at Knauer is complemented by an increasing appetite for transformative investments. However, such optimism risks being obscured by the demands of its new major shareholder, PartnerFonds (44%), even if hitherto settled judicially in favour of Blue Cap management, and now looking to be resolved amicably in the interests of all shareholders. Despite more challenging conditions (consensus forecasts have been reduced), the 40% share price discount to NAV (â‚¬29.55 at December 2018) appears excessive.

10/05/2019 5 EN

Underlying

Blue Cap

Blue Cap AG is a Germany-based holding company investing in medium-sized companies in the industry sector. The Company's portfolio includes companies in the areas of adhesives, special machinery, medical and measurement technology and precious metals. It distinguishes five business segments: Coating technology, Adhesive technology, Production technology, Medical technology, Precious metal recycling and trade. Its portfolio companies include NESCHEN Coating GmbH, a producer of adhesive-coated films; PLANATOL GmbH, a producer of glues; Gaemmerler GmbH, a manufacturer of printing systems; nokra Optische Prueftechnik und Automation GmbH, a provider of measuring and testing systems; em-tec GmbH, a developer of blood flow measuring devices; INHECO Industrial Heating and Cooling GmbH, a developer of thermo-electric components; Carl Schaefer Gold- und Silberscheideanstalt GmbH, a precious metals processing company, and knauer Holding GmbH & Co KG, a plastic cup supplier, among others.

See profile

DE000A0JM2M1 Germany

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Richard Finch

Other Reports on these Companies

SmartInsider

Blue Cap AG: 1 director

A director at Blue Cap AG bought 2,000 shares at 17.865EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Free Trial

March 14, 2024 March 14, 2024 1 EN

EQS Group AG

EQS-News: Blue Cap AG achieves EBITDA margin (adj.) of 8.5% in 2023 and announces outlook for 2024

EQS-News: Blue Cap AG / Key word(s): Preliminary Results Blue Cap AG achieves EBITDA margin (adj.) of 8.5% in 2023 and announces outlook for 2024 13.03.2024 / 07:09 CET/CEST The issuer is solely responsible for the content of this announcement. Group revenue of EUR 273.3 million in line with guidance Adjusted EBITDA of EUR 23.2 million results in an adjusted EBITDA margin of 8.5 % Fourth quarter was characterized by increasing momentum and positive effects from turnaround measures Earnings expected to increase in 2024 with slight growth in revenue Munich, March 13, 20...

March 13, 2024 March 13, 2024 1 EN

EQS Group AG

EQS-News: Blue Cap AG erreicht 2023 EBITDA-Marge (adj.) von 8,5% und gibt Ausblick für 2024 bekannt

EQS-News: Blue Cap AG / Schlagwort(e): Vorläufiges Ergebnis Blue Cap AG erreicht 2023 EBITDA-Marge (adj.) von 8,5% und gibt Ausblick für 2024 bekannt 13.03.2024 / 07:09 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Adjusted EBITDA von 23,2 Mio. Euro ergibt adjusted EBITDA-Marge von 8,5 % Viertes Quartal war geprägt von anziehender Dynamik und positiven Effekten aus Turnaroundmaßnahmen Für 2024 wird ein Anstieg des Ergebnisses bei gering wachsendem Umsatz erwartet München, 13. März 2024 – Die Blue Cap AG („Blue Cap“) blickt nach...

March 13, 2024 March 13, 2024 1 DE

discoverIE Group - FY24 EPS in line; good margin progress

discoverIE anticipates reporting FY24 underlying EPS in line with board expectations. After a period in mid-FY24 of working down inventory, customers appear to be reverting to normal ordering patterns, with Q424 organic revenue growth of 2% y-o-y and 11% q-o-q and a strong pipeline of design wins at year-end. We have revised our forecasts to reflect lower revenue, partly due to a disposal, but maintain our profit forecasts, which results in operating margin expansion in FY24 and FY25.

22h / 44m 22h / 44m 1 EN

Sean Conroy

Sean Conroy

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - AbbVie deal clears antitrust hurdle

OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE’s runway extension into 2026, past key milestones and readouts for in-house assets Tedopi (non-small cell lung cancer, US Phase III trials expected to commence in Q224) and Lusvertikimab (ulcerative colitis, Phase II readouts expected in mid-2024). Following the Federal Communications Commission (FCC) mandatory waiting period, OSE is expected to receive the negotiated US$48m upfront payment from AbbVie imminently, as part of its gl...

April 18, 2024 April 18, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN